Tarsus Pharmaceuticals, Inc.
TARS
주식 순위
#4560
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
주가
$70.82
마지막 동기화: 2026-10-21
시가총액
$3.31B
변동 (1일)
-0.30%
변동 (1년)
3.08%
국가
US
거래 Tarsus Pharmaceuticals, Inc. (TARS)
카테고리
Healthcare
Tarsus Pharmaceuticals, Inc. (TARS)의 주가 이력
최고 종가: $72.26 (2026-10-01 기준)
최저 종가: $21.51 (2020-10-01 기준)
최저 종가: $21.51 (2020-10-01 기준)
Tarsus Pharmaceuticals, Inc.의 주가 이력 (2020 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
